RESUMEN
AIM: To determine whether 'MGP' gutta-percha (Westport, CT, USA), a commercially available gutta-percha containing iodoform, inhibits the growth of potential endodontic pathogens. METHODOLOGY: Inocula of Enterococcus faecalis, Staphylococcus aureus, Escherichia coli, Pseudomonas aeruginosa, Streptococcus sanguis, Fusobacterium nucleatum and Actinomyces odontolyticus were spread onto the surface of agar plates. 'MGP' gutta-percha cones presoaked in sterile water were transferred to the inoculated agar and incubated at 37 degrees C aerobically or anaerobically as required for optimal growth. Identical studies were performed using iodoform-free gutta-percha and sterile paper disks saturated with 10% povidone-iodine. Following incubation, zones of inhibition around the 'MGP' gutta-percha, iodoform-free gutta-percha and disks were evaluated. RESULTS: Povidone-iodine inhibited all the strains. Iodoform-free gutta-percha inhibited S. sanguis and A. odontolyticus. 'MGP' gutta-percha inhibited S. aureus, S. sanguis, A. odontolyticus and F. nucleatum. Neither iodoform-free gutta-percha nor 'MGP' gutta-percha inhibited growth of E. faecalis, E. coli or P. aeruginosa. CONCLUSIONS: Compared to iodoform-free gutta-percha, iodoform-containing 'MGP' gutta-percha had an inhibitory effect in vitro on S. aureus and F. nucleatum, but not on E. faecalis, E. coli or P. aeruginosa.
Asunto(s)
Antiinfecciosos/farmacología , Bacterias/efectos de los fármacos , Gutapercha/farmacología , Hidrocarburos Yodados/farmacología , Materiales de Obturación del Conducto Radicular/farmacología , Actinomyces/efectos de los fármacos , Antiinfecciosos Locales/farmacología , Enterococcus faecalis/efectos de los fármacos , Escherichia coli/efectos de los fármacos , Fusobacterium nucleatum/efectos de los fármacos , Humanos , Povidona Yodada/farmacología , Pseudomonas aeruginosa/efectos de los fármacos , Staphylococcus aureus/efectos de los fármacos , Streptococcus sanguis/efectos de los fármacos , TemperaturaRESUMEN
The activity of RP 59500 (quinupristin/dalfopristin) was evaluated in vitro against antibiotic-resistant strains of Streptococcus pneumoniae (N = 15) and Enterococcus spp. (N = 43). By broth dilution MIC tests RP 59500 was highly active against penicillin-resistant S. pneumoniae and vancomycin-resistant Enterococcus faecium, but showed poor activity against E. faecalis. In time-kill studies the drug was rapidly bactericidal against S. pneumoniae but failed to kill most enterococci, even in the presence of gentamicin or human serum.